Revolutionary Patent for Pinfenon in Canine Cardiac Health
Scarecrow Incorporated has made a significant breakthrough by securing a patent for Pinfenon (S) (R), an innovative animal supplement designed to address cardiac health issues in dogs. This pioneering supplement adds a new dimension to veterinary care by providing treatment and prevention methods for cardiac disorders in pets.
Understanding Cardiac Disorders in Dogs
Cardiac disorders are increasingly prevalent among dogs, particularly in small breeds. Conditions such as mitral regurgitation, which is a common heart disease, can severely impact a dog's quality of life and longevity. This disorder is notably associated with elevated levels of a hormone known as atrial natriuretic peptide (ANP), which serves as a biomarker for heart health.
The Significance of ANP in Canine Health
ANP is produced in the heart's atrium and released into the bloodstream, where it can be monitored through simple blood tests. Elevated ANP levels indicate heart strain, making it crucial for detecting and managing cardiac disorders in dogs. The newly patented Pinfenon has shown promising results in lowering ANP levels, thus alleviating the burden on canine hearts.
Development of Pinfenon and Clinical Insights
Before its patent acquisition, Pinfenon (S) (R) underwent rigorous clinical trials involving 27 dogs diagnosed with mitral regurgitation at multiple veterinary hospitals. In this study, dogs received Pinfenon in conjunction with their regular heart medications over a period of 30 days. Observations indicated a remarkable decline in ANP levels, demonstrating the supplement's efficacy in improving cardiac health.
Comprehensive Study Findings
Results from the clinical study highlighted not only a significant reduction in ANP but also improvement in clinical symptoms, especially in breathing difficulties associated with cardiac issues. This data emphasizes the potential of Pinfenon as a transformative approach to managing heart health in dogs.
Innovative Ingredients of Pinfenon
The primary ingredient in Pinfenon is extracted from the French maritime pine bark, well-known for its high physiological potency. This natural compound, combined with other supportive ingredients like fermented sesame extract and yeast extract, creates a robust formulation intended to enhance the overall health of animals.
The Process of Patent Acquisition
The Japan Patent Office has recognized the novel aspects of Pinfenon as a treatment and preventative measure against elevated ANP levels. The patent encompasses not only the composition of the supplement but also the methods of manufacturing, which can be utilized across various products including pet foods and topical applications.
About Scarecrow Incorporated
Founded in the heart of Japan, Scarecrow Incorporated is dedicated to advancing animal health through scientific research and innovation. With a commitment to quality and efficacy, they have carved a niche in developing supplements aimed at enhancing the well-being of pets globally. Their comprehensive approach in research ensures that their products are backed by clinical data, making them a trusted name in veterinary medicine.
Frequently Asked Questions
What is Pinfenon used for?
Pinfenon is designed to lower cardiac disorder markers, specifically atrial natriuretic peptide (ANP), in dogs, thus improving their heart health.
How does Pinfenon work?
It works by utilizing natural extracts that help reduce heart strain and improve overall cardiac function in dogs.
Is Pinfenon safe for all dog breeds?
Yes, Pinfenon is formulated to be safe for various breeds, especially small dogs that are predisposed to cardiac issues.
What were the outcomes of the clinical study?
The study showed significant reductions in ANP levels and improvements in breathing difficulties among the treated dogs.
Who developed Pinfenon?
Pinfenon was developed by Scarecrow Incorporated, with the formulation attributed to researchers including Hiroshi Okawa and Hiroshi Koie.
